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1. Introduction 
Infective endocarditis (IE) is an endovascular infection of cardiovascular structures – usually 
valves – but also large intra-thoracic vessels and intra-cardiac foreign bodies. It is typically 
caused by bacteria or fungi. In contrast, sterile thrombotic lesions are termed non-bacterial 
thrombotic endocarditis (NBTE). IE is generally characterised by lesions of vegetations 
composed of platelets, fibrin, microorganisms, and inflammatory cells, as well as leaflet 
disruption to a various degree. Endocarditis may also produce a wide variety of systemic 
signs and symptoms due to sterile and infected emboli, as well as various immunological 
phenomena. IE is a fatal disease if left untreated (Horstkotte et al., 2004). 
Characterising aspects of IE were first described by Jean François Fernel in his book 
Medicini in 1554. Lazaire Riviere followed suit with gross autopsy findings of the disease in 
1723 after which, in 1852, Kirkes described emboli arising from heart valves in cerebral, 
renal, splenic and other arteries. Although several reports of IE have been published since – 
some from well-known physicians like Morgagni and Virchow, it was not until 1885 that IE 
was comprehensively documented when Sir William Osler accumulated various works and 
presented them to the public in the form of the comprehensive analysis of this disease 
(Millar & Moore, 2004).  
Despite substantial improvements in diagnosis and treatment of native valve IE, disease 
incidence is on an increase currently averaging 3.3 new cases each year per 100,000 
population in the United Kingdom, similar figures in the United States, and 1.4 to 4 new 
cases over the same population in European countries (Bashore et al., 2006). Native valve IE 
continues to be associated with high morbidity and mortality rate. Even though IE was 
previously associated with poor dentition and rheumatic heart disease, many factors have 
altered its epidemiology but have maintained its incidence: an aging population with 
degenerative valvular disease, injection drug use, increasing number of valve replacements, 
and medical interventions i.e. invasive vascular procedures (Wang & Bashore, 2009). Several 
variants to valve endocarditis have also been recognized: nosocomial IE, intravenous drug 
abuse IE, and prosthetic valve endocarditis (PVE). Nosocomial infective endocarditis is 
defined as acute IE, occurring 48 to 72 hours or more post-admission to hospital, or 
endocarditis directly related to a hospital-based procedure performed during a prior 
hospital visit within eight weeks of admission (Haddad et al., 2004). Intravenous drug abuse 
IE most commonly affects tricuspid valve and is associated with no previous structural 
damage of the valve. PVE accounts for 10-20% of cases. Incidence of PVE is reported to be 
most often between 0.2 and 0.8% for each year of life with an implanted valve (Dominik & 
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Zacek, 2010). Two forms of PVE can be distinguished: early PVE that occurs within 60 days 
of valve implantation, and late PVE occurring 60 days or more after valve implantation. It is 
more common after aortic than after mitral valve replacement and affects mechanical and 
bioprosthetic valves equally (Baddour & Wilson, 2005).  
IE may give rise to numerous extracardiac, cardiac, and valvular findings, including 
infected thrombi (vegetations), sequel of local tissue destruction, and systemic 
manifestations including vasculitis, emboli, and ischemic events (Kwan-Leung & Embli, 
2006). The classic clinical presentation of IE may be characterized as acute or subacute-
chronic. Acute IE develops abruptly and progresses rapidly irrespective of person’s health 
or debilitation level. A source of infection or portal of entry is often evident. When bacteria 
are virulent or bacterial exposure is massive, acute IE can affect normal valves. It is usually 
presented with signs of hemodynamic deterioration due to valve destruction caused by 
more aggressive forms of pathogens. The course of subacute IE is more subtle yet harder to 
diagnose, and may extend over many months. Often no source of infection or portal of entry 
is evident. 
Nowadays, echocardiography offers a highly accurate diagnostic mechanism aimed at early 
detection and recognition of this disease and its complications also in the absence of positive 
blood cultures. Trans-esophageal echo (TEE) is preferred over trans-thoracic echo (TTE) 
because of its high sensitivity and greater ability to visualize local spread of infection at an 
early stage. Valve incompetence with left ventricular decompensation and congestive heart 
failure is the usual hemodynamic complication. Surgically demanding cases are those that 
affect periannular tissue and lead to significantly increased mortality and the rate of 
recurrent infection (Knosalla et al., 2000). Local spread of infection occurs in about 10 to 40% 
of native valve IE (Kang et al., 2009). Potential complications from a periannular progression 
of IE include abscess formation, pseudoaneurysm formation of the mitral-aortic 
interventricular fibrosa and the subsequent development of aorto-cavitary fistula (ACF). It is 
estimated that 1.5-2.2% of the patients with IE of aortic valve will develop ACF, more 
frequently those with prosthetic valve IE than those with native valve IE (odds 1.61:1) 
(Anguera et al., 2005). ACF is the most dangerous complication of periannular tissue 
involvement with the mortality of up to 40%. Extension of the IE from aortic to the mitral 
valve is possible and occurs through mitro-aortic fibrous continuity with development of a 
septic aneurysm in the anterior mitral leaflet with or without perforation. 
2. Pathogenesis 
Several conditions must be met in order to develop IE. According to the injury-thrombus-
infection theory, the trigger event is the endocardium damage. Endothelial injury is the 
most plausible factor leading to platelet deposition. Injury develops as a result of 
hemodynamic and mechanical stress to the endocardium. The predilection site of IE is 
rough part of the valves (the coaptation area) due to high impact pressures following the 
closure of the leaflets. Also, turbulent blood flow produced by congenital or acquired heart 
diseases traumatizes the endothelium inducing apoptosis of valve cells and leading to tissue 
remodelling. As a result, platelet and fibrin deposition occurs. The phase in which sterile 
thrombotic vegetations are present on the leaflets is referred to as NBTE. The Venturi effect 
also contributes to the development and location of NBTE, i.e. vegetations are attached to 
the flow side of the valves (ventricular side of semilunar valves, tips of the leaflets, sewing 
rings of prosthetic valves) (Bashore et al., 2006). The entry of micro-organisms into the 
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circulatory system leads to bacteremia and ultimately converts NBTE into IE. Naturally this 
would depend on the bacteria inoculum sufficient to allow invasion of the pre-existing valve 
thrombus. Clinical manifestation of IE appears to be influenced by several factors both host 
and pathogen related (susceptibility of the host genetically determined by defence 
mechanisms and adherence propensity as well as invasiveness of certain pathogens) (Naber 
et al., 2009).  
On gross examination, vegetations are usually grey, pink, or brown and are often friable. 
They may be single or multiple and may affect more than one valve. Vegetations may be 
located anywhere on the valve cusp or leaflet or endocardial surface. In fact this is an 
important distinguishing feature to note, as valve thrombi associated with nonbacterial 
thrombotic endocarditis (NBTE) and those related to rheumatic fever do not have this 
variability in location, and are usually along the lines of valve closure (Kwan-Leung &  
Embli, 2006). Corresponding microscopic finding would depend on the virulence and 
duration of the induction and is usually characterized with presence of fibrin, neutrophils 
and clumps of organisms with foci of calcification or organized thrombi to a certain extent. 
2.1 Microbiology 
The common causes of native valve IE include members of the normal bacterial flora of the 
skin, oropharynx and the gastrointestinal and genitourinary tract (Kwan-Leung & Embli, 
2006). The most common microorganisms that cause IE include: Streptococci, Staphylococcus 
aureus, Enterococcus species, HACEK organisms (Hemophilus parainfluenzae, Hemophilus 
aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella species, 
and Kingella species) and fungi (Bayer et al., 1998). S. aureus is more often associated with the 
native valve IE than PVE, whereas coagulase negative Staphyloococci are more commonly 
seen in PVE. Furthermore, Enterococcus spp. usually leads to subacute form of IE. Anaerobic 
bacteria are rarely associated with IE and account 2-16% of all cases (Brook, 2008). Candida 
and Aspergillus species cause the majority of fungal IE (Bayer et al., 1998). Intravenous drug 
abusers, prosthetic-valve recipients, and patients with long-term central venous catheters 
are at highest risk for fungal IE. Fungal infected thrombi are usually quite large and friable 
leading to valve orifice obstruction. 
 
Procedure Rate Micro-organisms 
Endoscopy 0-20% 
Coagulase negative 
Staphylococi, Streptococci, 
diphteroids 
Colonoscopy 0-20% 
Escherichila coli, Bacteroides 
species 
Barium enema 0-20% 
Enterococci, aerobic and 
anaerobic gram-negative rods 
Dental extractions 30-100% Streptococcus viridans 
Transurethral resection 
of the prostate 
20-45% 
Coliforms, Enterococci, 
Staphylococcus aureus 
Transesophageal 
echocardiography 
0-25% 
Streptococcus viridans, 
anaerobic organisms, 
Streptococci 
Table 1. Rate of subsequent bacteraemia following certain procedures 
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Microorganisms have surface adhesions that mediate the adherence to vegetation and 
avidly bind to valvular and peri-annular tissue with irreversible adhesion (Mocchegiani & 
Nataloni, 2009). They then produce a biofilm that inhibits host’s defence mechanisms and to 
protect themselves against antimicrobial treatment. This makes antibiotic sterilization 
extremely difficult. Causative microorganisms vary by site of infection, source of bacteremia, 
and host risk factors as shown in Table 1 (Towns & Reller, 2003). 
Blood culture negative endocarditis (BCNE) is by definition IE in which standard culture 
methods are inadequate to allow detection of the causative agents. The incidence of BCNE 
have historically ranged from 2.5% to 31% depending on the study population (Kwan-
Leung & Embli, 2006). The most common pathogens that cause BCNE are: Coxiella burnetti, 
Bartonella spp. and Trophyrema whipplei. IE associated with these microorganisms most often 
occurs in patients with some form of immunodeficiency, valvular disease and a history of 
contact with domestic animals. 
3. Clinical presentation and diagnosis 
The diagnosis of IE is based upon clinical suspicion derived from signs and symptoms and 
most importantly the demonstration of associated bacteremia. Clinical presentation of IE 
may vary significantly with regards to causative pathogen, immunological status of the host, 
intermittent use of antibiotics, structural heart disease, and presence of foreign objects (heart 
valves, pacemakers etc.). The diagnosis of IE is straightforward in those patients with classic 
manifestations: bacteremia or fungemia, evidence of active valvulitis, peripheral emboli, and 
immunologic vascular phenomena (Bayer et al., 1998). In other patients however the classic 
peripheral stigmata may be few or absent. All this imposes the necessity for highly sensitive 
diagnostic algorithm that will be both sensitive for disease detection and specific for its 
exclusion across all the forms of the disease (Baddour et al., 2005). 
Initial signs and symptoms of subacute IE may be vague and ambiguous: low grade fever, 
fatigability and malaise, night sweats, and weight loss. Clinical manifestation may be 
prolonged until the development of a heart murmur with or without signs of valvular 
insufficiency. From this point on, diagnosis can be readily established. However, majority of 
the patients already have detectable heart murmurs and with a coinciding clinical 
presentation, IE should be suspected. Peripheral lesions of subacute IE include: petechiae 
(oral mucosa, conjunctivae, the dorsa of the hands and feet, chest and abdominal wall), 
subungal haemorrhages (splinter haemorrhages), Osler nods, clubbing fingers, Roth spots 
(round or oval haemorrhagic retinal lesions), Janeway lesions (irregular erythematous and 
painless macules on palms and soles). In current times of widespread use of antibiotics, 
incidence of classic presentation of the peripheral lesions reduced substantially. Some of the 
peripheral manifestations develop as a result of immunological activities, while others result 
from embolization. About 35% of patients may develop central nervous system effects such 
as transient ischemic attacks, stroke, toxic encephalopathy, and brain abscess (Baddour et 
al., 2005). Renal embolization may lead to hematuria while splenic emboli may cause left 
upper quadrant pain. 
Acute IE is characterized by a more rapid and progressive course of the disease. The 
invasiveness and aggressiveness of the pathogen causes prompt reaction in the host 
including hyperpyrexia, profuse sweating, fatigue, and malaise. Signs and symptoms of 
heart failure develop very often and heart murmur is present in almost every case. 
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Definite IE 
 Pathological criteria 
  Microorganisms demonstrated by culture or histological examination of 
a vegetation, a vegetation that has embolized, or an intracardiac 
abscess specimen; or 
Pathological lesions; vegetation or intracardiac abscess confirmed by 
histological examination showing active endocarditis 
 Clinical criteria 
  2 major criteria; or 
1 major criterion and 3 minor criteria; or 
5 minor criteria 
Possible IE 
  1 major criterion and 1 minor criterion; or 3 minor criteria 
Rejected 
  Firm alternative diagnosis explaining evidence of IE; or 
Resolution of IE syndrome with antibiotic therapy for 4 days; or 
No pathological evidence of IE at surgery or autopsy, after antibiotic 
therapy for 4 days; or 
Does not meet criteria for possible IE as above 
 
Table 2. Definition of IE according to the modified Duke criteria (Li et al., 2000) 
 
Major blood culture criteria include 
 Two blood cultures positive for organisms typically found in patients with IE 
(i.e., S viridans, Streptococcus bovis, a HACEK group organism, community-
acquired S aureus, or Enterococci in the absence of a primary focus) 
 Blood cultures persistently positive for one of the above organisms from 
cultures drawn more than 12 hours apart 
 Three or more separate blood cultures drawn at least 1 hour apart 
 Single positive blood culture for Coxiella burnetii or anti–phase 1 
IgG antibody titer > 1:800 
Major echocardiographic criteria include 
 Echocardiogram positive for IE, documented by an oscillating intracardiac 
mass on a valve or on supporting structures, in the path of regurgitant jets, or 
on implanted material in the absence of an alternative anatomical explanation 
 Myocardial abscess 
 Development of partial dehiscence of a prosthetic valve 
 New-onset of valvular regurgitation 
Minor criteria include 
 predisposing heart condition 
 fever 
 temperature > 38º 
 vascular phenomena or immunologic phenomena 
 microbiological evidence that does not meet a major criteria 
 
Table 3. Definition of terms used in the modified Duke criteria for IE diagnosis (Li et al., 2000) 
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With regard to recurrence of IE, two types are described: relapse – repeat episodes of IE 
caused by the same microorganism < 6 months after the initial episode; and reinfection – 
infection with a different microorganism or repeat episode of IE caused by the same 
microorganism > 6 months after the initial episode. 
IE diagnostic criteria published in the previous studies were refined by Durack and 
colleagues from Duke University Medical Center in 1994. These criteria, which have come to 
be known as the Duke criteria, incorporated echocardiographic evidence of endocardial 
involvement (Table 2, Table 3) (Durack et al., 1994; Li et al., 2000). The criteria had improved 
test performance characteristics over the prior set and have been validated subsequently by 
many other studies (Wang & Bashore, 2009). 
European society of cardiology published diagnostic criteria that should raise suspicion of 
IE (Table 4) (Horstkotte et al., 2004). These overlap the Duke criteria to an extent, but are 
also notably different.  
 
High clinical suspicion (urgent indication for echocardiographic screening and possibly 
hospital admission) 
 new valve lesion/(regurgitant) murmur 
 embolic event(s) of unknown origin (esp. cerebral and renal infarction) 
 sepsis of unknown origin 
 haematuria, glomerulonephritis, and suspected renal infarction 
 fever plus one or more of these: 
  prosthetic material inside the heart; other high predispositions for IE; newly 
developed ventricular arrhythmias or conduction disturbances; first 
manifestation of CHF; positive BCs (if the organism identified is typical for 
NVE/PVE); cutaneous (Osler, Janeway) or ophthalmic (Roth) manifestations; 
multifocal/rapid changing pulmonic infiltrations (right heart IE); peripheral 
abscesses (renal, splenic, spine) of unknown origin; predisposition and recent 
diagnostic/therapeutic interventions known to result in significant  
Low clinical suspicion 
 fever plus none of the above 
IE – Infective endocarditis; CHF – Congestive heart failure; BC – Blood cultures; NVE – Native 
valve endocarditis; PVE – Prosthetic valve endocarditis  
Table 4. Criteria that should raise suspicion of IE (Horstkotte et al., 2004) 
Although differential diagnosis may seem abundant, after careful clinical management it 
can be reduced to: non-infectious endocarditis (marantic endocarditis – paraneoplastic 
syndrome associated with some malignancies and Libman-Sacks endocarditis – associated 
with systemic lupus erythematosis), and cardiac tumors (atrial myxoma and valve 
fibroelastoma) (Velicki et al., 2010). 
3.1 Echocardiography 
Echocardiography plays a crucial role in the diagnosis and management of IE. Diagnosis 
should be based on the isolation of the microorganism through the blood cultures. In certain 
cases blood cultures would yield inadequate (non-diagnostic) results due to changing nature 
of valvular infection necessitating reliance on echocardiography as an indirect diagnostic 
method. Echocardiography is useful not only for assessing the structural and functional 
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valvular status, but also for the local spread of infection (annular abscess or ACF), as well as 
predicting the potential for embolization. Echocardiography should be performed in all 
cases of suspected IE (Baddour et al., 2005). 
In most cases TTE would be sufficient in evaluation of aortic valve endocarditis. TEE may be 
indicated in case of PVE suspicion, evaluation of local spread of infection (better 
visualization of abscess cavities and ACF), as well as predicting embolization potential 
based on the vegetation size, consistency, location, number and mobility. Both TTE and TEE 
can produce false-negative and false-positive results on rare occasions (too small vegetations 
or already dislodged vegetations, valvular abnormalities not related to a current infection, 
respectively). Echocardiography should therefore be only one step in a diagnostic chain. 
More recent studies have shown that in majority of clinical situations of suspected IE, an 
initial strategy of TEE is more cost-effective than a staged procedure with TTE and is 
therefore an optimal strategy over empiric antibiotic therapy alone (Habib et al., 2009). At 
the same time it is important to outline specific definitions of the echocardiographic findings 
to adequately evaluate local endocarditis presentation (Table 5) (Sachdev et al., 2003). 
 
Finding Description 
Vegetation 
Irregularly shaped, discrete echogenic mass, adherent to but 
distinct from endocardial surface or intra-cardiac device 
Oscillation of mass (supportive, not mandatory) 
Abscess 
Thickened area or mass within the myocardium or valve annulus, 
or evidence of flow into region (supportive, not mandatory) 
Aneurysm Echolucent space with thin surrounding tissue 
Fistula 
Blood flow between two distinct cardiac blood spaces or chambers 
through abnormal path/channel 
Leaflet perforation Defect in body of valve leaflet with flow through defect 
Valve dehiscence 
Prosthetic valve with abnormal rocking motion/excursion in at 
least one direction 
Table 5. Echocardiographic findings in IE and corresponding definitions (Sachdev et al., 
2003)  
3.2 Periannular extension 
Periannular extension of infection is one of the most fearful complications in patients with 
IE. Perivalvular extension in the setting of native valve IE develops from bacterial necrosis 
of local tissue and results in high rates of heart failure and death despite surgical therapy 
(Anguera et al., 2006). Local spread of infection occurs in about 10 to 40% of native aortic 
valve endocarditis (Kang et al., 2009).  
Periannular abscess formation and aortocavitary fistulous tract formation in IE represent a 
further step in aortic annular erosion and the extension of infection beyond the leaflets and 
the aortic ring. In the early stage, perivalvular abscess is largely composed of inflammatory 
infiltrate, but at later stages necrosis and cavitation usually develop leading to destruction of 
perivalvular tissue. Perivalvular abscess is not a static complication but is progressive and 
can evolve into serious perivalvular complications including perivalvular leak, fistula and 
pseudoaneurysm (Kwan-Leung &  Embli, 2006). It is estimated that 1.5-2.2% of patients with 
IE of aortic valve will develop ACF, and even more frequently those with PVE as opposed to 
those with native valve endocarditis (odds 1.61:1) (Anguera et al., 2005). Due to the central 
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position of the aortic valve, infection of the valve may form fistulas with practically any 
surrounding chamber (Susak et al., 2009). Because PVE usually begins as periannulitis, it is 
not surprising that infected prosthetic valves have these complications with a higher 
frequency than native valves. ACF is the most dangerous complication of periannular tissue 
involvement with the mortality of up to 40% (Kang et al., 2009). It is estimated that around 
60% of patients with ACF develop heart failure before surgery and the extent of the heart 
failure is more severe than in patients with nonruputred abscesses (Anguera et al., 2006). 
Extension of the IE from aortic to the mitral valve occurs through mitro-aortic fibrous 
continuity with development of a septic aneurysm in the anterior mitral leaflet with or 
without perforation. Myocardial ischemic sequelae may develop as a result of debris 
embolization from aortic root abscess, or due to extraluminal compression from an enlarged 
aortic root abscess. Coronary arteries can become directly affected by local extension 
through the coronary ostia or by creation of mycotic aneurysms. 
In the published data, one of the most convincing and consistently reliable variables 
predictive of periannular complications has been the appearance of an AV block and signs 
of pericarditis or pericardial effusion (Graupner et al., 2002). Most of these patients will 
undergo surgery because of classic surgical indications independent of the 
echocardiographic detection of periannular complications. 
 
 
Fig. 1. TEE showing: (A) possible fistula, (B) perforation of the right coronary leaflet,  
(C) Color flow imaging of the aortic valve showing severe aortic regurgitation due to leaflet 
perforation, (D) vegetations on the aortic side of the leaflets 
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Fig. 2. IE superimposed on severe aortic stenosis with development of small friable 
vegetations and leaflet abscess 
 
 
Fig. 3. Complete destruction of the right coronary leaflet (A and B), small vegetations on all 
leaflets (A, B, C) and ACF to the right ventricle with probe in it (D) 
www.intechopen.com
 Aortic Valve 
 
82 
3.3 Prosthetic valve endocarditis 
PVE is defined as infection occurring in a prosthetic heart valve and has an overall incidence 
of 0.32% to 1.2% per patient year and cumulative risk of 5% at 10 years (Mahesh et al., 2005). 
Rates range from 1% to 3% within the first year however the highest rate of infection occurs 
in the first three postoperative months. By six months, rates stabilize to 0.4% annually 
(Kwan-Leung & Embli, 2006). Despite advances in diagnosis, medical and surgical therapy 
over the past few decades, PVE still carries a substantial risk of morbidity, with overall 
mortality ranging from 20% to 80% of affected patients (Musci et al., 2010). Important factors 
in the pathogenesis include type of prosthesis, previous native valve endocarditis, male 
gender, and long cardiopulmonary bypass time. A number of studies have reported a 
higher incidence of PVE after mechanical valve replacement in comparison with the biologic 
valve replacement during the initial few months after implantation. Early PVE may develop 
when pathogens reach the valve prosthesis by way of direct contamination intraoperatively 
or via hematogenous spread over the initial days and weeks after surgery. The pathogens 
have direct access to the prosthesis-annulus interface and to perivalvular tissue along suture 
pathways because the valve sewing ring, cardiac annulus, and anchoring sutures are not 
endothelialized early after valve implantation. These structures are coated with host 
proteins such as fibronectin and fibrinogen to which some organisms can adhere to and 
initiate infection. On the other hand, as the sewing ring, sutures, and adjacent tissues 
become endothelialized in months after valve replacement, sites for adherence of 
microorganisms and access to host tissues adjacent to the prosthesis are altered. The 
pathogenesis of late PVE has been postulated to resemble native valve endocarditis. This 
temporal classification is based on marked differences in microbiologic causes of early and 
late PVEs. Early PVE accounts for approximately 30% of all PVE cases and is predominantly 
caused by S. aureus, gram-negative bacilli, and coagulase negative Staphylococci. There are 
also differences in infection localization with regard to type of prosthesis used to replace 
aortic valve. Infections in mechanical valves generally involve the sewing ring or adherent 
thrombi, and can lead to paraprosthetic leaks, ring abscesses, and invasive infection, 
necessitating operative intervention. Bioprostheses are less susceptible to early infection, 
which is often restricted to the leaflets, making cure with antibiotics more likely but 
increasing the chances of late failure due to degeneration of the cusps (Mahesh et al., 2005). 
Severe heart failure, staphylococcal infection and complicated PVE are designated as 
markers of both in-hospital and late mortality, while severe heart failure and S. aureus 
infection were the only independent predictors of in-hospital death (Habib et al., 2008). Data 
from the International Collaboration on Endocarditis showed that in-hospital death, which 
occurred in 22.8% of the study patients, was predicted by older age, health-care-associated 
infection, S. Aureus infection and complications of PVE, including heart failure, stroke, intra-
cardiac abscess and persistent bacteraemia (Wang et al., 2007).  
Because the presence of a prosthetic heart valve is a predisposing factor to the development 
of endocarditis, antibiotic prophylaxis and therapy at the time of health-care-related 
procedures has been a mainstay of care of the patient with a prosthetic valve (Wang & 
Bashore, 2009). For this reason, antibiotic prophylaxis is recommended only for patients 
with prosthetic heart valves prior to dental procedures (highest rate of possible bacteremia 
as demonstrated in Table 1.), but not before gastrointestinal or genitourinary procedures 
(Wilson et al., 2008). However, ESC guidelines do recommend antibiotic prophylaxis in the 
case of gastrointestinal or genitourinary procedures (Horstkotte et al., 2004). 
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Patients with suspected PVE should be aggressively treated with broad spectrum antibiotics 
that are effective against wide range of microorganisms especially staphylococci and 
streptococci. In further course of the disease, antibiotic regiment should be optimised based 
on sensitivity of isolated cultures. This therapy should reduce the risk of systemic 
embolization by shrinking the size of vegetations. Patient should be carefully monitored and 
further diagnostic procedures should be performed. TEE is of greatest value because it can 
provide information of existence and extension of infective process to a surrounding tissue. 
Negative echocardiography finding does not necessarily exclude PVE. After the diagnosis of 
PVE, repeat-TEE may be highly sensitive and useful to diagnose complications such as 
prosthetic valve dysfunction (regurgitation or stenosis), resultant changes in ventricular 
function or dilation, periannular extension of infection (intra-cardiac abscess or fistula 
formation), or involvement of other valves (Wang & Bashore, 2009). Surgical consultation 
should be promptly scheduled given that periannular complications occur in more than 50% 
of patients and may lead to complete aortic root destruction. Radical surgical debridement 
with a margin of healthy tissue to eradicate intracardiac foci of infection remains the 
primary aim of surgery for PVE, enabling secure fixation of the new prosthesis, avoiding 
recurrent or residual infection, periprosthetic leak or dehiscence, or subannular aneurysm 
formation (Mahesh et al., 2005). 
4. Clinical management 
The diagnosis of IE remains challenging and continues to be dependent on a constellation of 
infectious symptoms and signs in association with bacteremia, auscultatory evidence of 
valvular involvement, and signs of large and/or small-vessel peripheral arterial embolization 
(Kwan-Leung & Embli, 2006). With availability of technologically sophisticated imaging 
modalities, establishing IE diagnosis should not be very hard in theory. Recognition is the 
first step in proper management of IE. Rapid diagnosis, early risk stratification, institution of 
appropriate bactericidal therapy, and prompt recognition and treatment of complications 
are the key elements toward a good outcome (Wang & Bashore, 2009).  
 
CLINICAL SUSPICION OF IE
TTE
  prosthetic
   valve or
intracardiac
    device
poor quality
      TTE
positive negative
  clinical
suspicion
   of IE
High    Low
TEE                                     TEE      Stop  
Fig. 4. Indications for initial echocardiography assessment. If initial TEE is negative but 
suspicion for IE remains, repeat TEE within 7-10 days (Habib et al., 2009) 
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Diagnosis should be established in regards to clinical presentation and IE diagnostic criteria 
presented in Table 2., Table 3. and Table 4. Blood cultures remains the single most important 
investigation in a patient suspected of having IE (gold standard test). If appropriate samples 
are obtained, one could expect to yield growth of the causative organism in over 90% of 
cases of IE (Kwan-Leung & Embli, 2006). At a minimum, 3 sets of blood cultures should be 
drawn at least 1h apart prior to antibiotic administration irrespective of body temperature. 
In most cases, the results of blood cultures would be available within 3 days from the 
moment they were obtained.  
Broad-spectrum parenteral antibiotic therapy should be commenced immediately upon 
suspicion of IE but after the acquisition of blood cultures. Antibiotic therapy should not be 
delayed (i.e. should be started even if the blood cultures are not drawn) only when dealing 
with septic patients with suspected IE. Therapy should be adjusted according to blood 
culture findings. It should continue for 4-6 weeks so as to eradicate all the pathogens from 
phagocytic cells and inaccessible vegetations. The precise antibiotic regiment for specific 
pathogens is presented in detail within the European Society of Cardiology 
recommendations (Horstkotte et al., 2004). The patient should be evaluated for the signs of 
immunodepression, malnutrition, or other systemic diseases as these conditions may impair 
the treatment course and promote development of complications. Additionally, renal 
function should also be carefully monitored, and due consideration given to probiotic 
supplements. 
Further clinical investigation should be performed using echocardiography and other 
diagnostic procedures guided by the clinical presentation. As stated earlier, TEE is preferred 
over TTE because of higher sensitivity and specificity, but TTE may serve as an initial 
screening test. If echocardiography remains negative but suspicion remains, echocardiography 
should be repeated within one week. A repeatedly negative study will near-exclude the 
diagnosis.  
Upon completion of the antibiotic regiment, or in the onset of complications or severe 
hemodynamic deterioration, the patient should be presented to cardiac surgeon to evaluate 
necessity for the operative intervention and its timing. Table 6 summarizes conditions 
considered as indications for surgical intervention.  
4.1 Surgical therapy 
Despite many advances in diagnosis and antibiotic therapy of IE, eradication of the septic 
focus and abolition of the accompanying systemic manifestations usually require some kind 
of surgical intervention. Surgically demanding cases are those of active IE affecting entire 
aortic root with development of local periannular complications. Main challenge with acute 
IE is to address the two coexisting aspects of the disease: the infectious process necessitating 
removal of all infected tissues to prevent recurrence, and altered valvular anatomy and 
function to be corrected and restored (Kwan-Leung & Embli, 2006). With regard to the 
complex pathology, the mortality and morbidity rates associated with surgical therapy 
remain relatively high - between 3.8 and 22% (d’Udekem et al., 1997). For the purpose of 
unifying criteria, hospital mortality is considered to be related to the operation when death 
occurs in the operating room or during the first 30 days after surgery, but also when the 
patient dies in hospital beyond 30 days without being discharged (Edmunds et al., 1996). 
There are many factors that may influence surgical mortality in IE giving cause to a risk 
stratification scoring system. 
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Indication Evidence 
Emergency indication for cardiac surgery (same day)  
 Acute AR with early closure of mitral valve A 
 Rupture of a sinus Valsalva aneurysm into a right heart chamber A 
 Rupture into the pericardium A 
Urgent indication for cardiac surgery (within 1–2 days)  
 Valvular obstruction A 
 Unstable prosthesis A 
 Acute AR or MR with heart failure, NYHA III–IV A 
 Septal perforation A 
 Evidence of annular or aortic abscess, sinus or aortic true or false 
aneurysm, fistula formation, or new onset conduction disturbances 
A 
 Major embolism + mobile vegetation >10mm + appropriate antibiotic 
treatment < 7–10 days 
B 
 Mobile vegetation > 15mm + appropriate antibiotic therapy < 7–10 
days 
C 
 No effective antimicrobial treatment available A 
Elective indication for cardiac surgery (earlier is usually better)  
 Staphylococcal prosthetic valve infective endocarditis B 
 Early prosthetic valve infective endocarditis (≤2 months after surgery) B 
 Evidence of progressive paravalvar prosthetic leak A 
 Evidence of valve dysfunction and persistent infection after 7–10 days 
of appropriate antibiotic treatment, as indicated by presence of fever 
or bacteremia, provided there are no noncardiac causes for infection 
A 
 Fungal infective endocarditis caused by a mould A 
 Fungal infective endocarditis caused by a yeast B 
 Infection with difficult-to-treat organisms B 
 Vegetation growing larger during antibiotic treatment > 7 days C 
A: Strong evidence or general agreement that cardiac surgery is useful and effective;  
B: Inconclusive or conflicting evidence or a divergence of opinion about the usefulness or 
efficacy of cardiac surgery but with weight of evidence & opinion of the majority being in 
favour; C: Inconclusive or conflicting evidence or divergence of opinion; lack of clear 
consensus on the basis of evidence or opinion of the majority. 
AR - aortic regurgitation; MR - mitral regurgitation; NYHA - New York Heart Association 
functional class. 
Table 6. Indications for surgical intervention in patients with IE (adapted from Delahaye et 
al., 2004) 
As shown in Table 6., indication for surgical intervention is usually based on development 
of heart failure that cannot be managed otherwise, signs of uncontrolled infection despite 
aggressive medical therapy, and manifestation or increased risk of embolization. These 
surgical indications stand for both native valve endocarditis and PVE. Prior to establishing 
an indication, surgeon must become aware of all the compromising factors that may affect 
the outcome of the surgery: phase of the infective process (acute or active phase is associated 
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with higher mortality), structural and functional status of afflicted valve, comorbidites). In 
patients with high risk of coronary heart disease, preoperative coronarography should be 
performed to assess the necessity of coronary artery bypass grafting in the same act. 
Knowing that cardiac surgery is an integral part of IE treatment strategy, it is advisable that 
cardiac surgery team should be included in patient evaluation following IE diagnosis. This 
will both enable the surgical team to become fully familiar with the patient case as the 
surgery is eventually called for, but also work with the medical team to determine the need 
and optimum timing for surgery (Kwan-Leung & Embli, 2006). 
4.1.1 Timing of surgery 
Surgical treatment is used in approximately half of patients with IE because of severe 
complications (Habib et al., 2009). The right timing of an operation is absolutely essential for 
success. The patient status has to be optimized to the maximum capacity in order to achieve 
maximal benefit from the operation. Operating too soon carries a higher risk of a failure due 
to unstable patient condition, specific cardiac tissue condition (friability) which may lead to 
embolization and peri-prosthetic leakage, and greater possibility of recurrence. On the other 
hand, waiting too long for the operative treatment may lead to a life-threating systemic 
infection (septic state) with development of multiple organ dysfunction syndrome, or 
extensive structural destruction of the heart valves and surrounding tissues. Surgical timing 
strategies have evolved significantly over the previous years, owing to the developments in 
the medical management and diagnostic tools, but despite this advent, when-to-operate still 
remains a controversial issue. 
In some cases surgery needs to be performed on an emergency (within 24 hours) or urgent 
(within a few days) basis irrespective of the duration of antibiotic treatment. In other cases 
surgery can be postponed to allow 1 or 2 weeks of antibiotic treatment under careful clinical 
and echocardiographic observation before an elective surgical procedure is carried out. 
Early surgical treatment is justified in patients with high-risk features that make unlikely the 
possibility of cure with antibiotic treatment, unless they also have co-morbid conditions or 
complications that make the prospect of recovery remote. 
According to European Society of Cardiology Guidelines (Habib et al., 2009), unless severe 
co-morbidity exists, early surgery is recommended in the following cases: the presence of 
heart failure, or presence of locally uncontrolled infection in the cases of native valve IE. The 
decision to operate-on early to prevent embolism is always difficult and specific for every 
patient. Governing factors include size and mobility of the vegetation, previous embolism, 
type of microorganism, and duration of antibiotic therapy. 
4.1.2 Types of surgical management 
During the preoperative evaluation and clinical management a surgeon is presented with a 
variety of information to evaluate and make an indication for surgical intervention. Exactly 
what type of intervention is going to be needed will be unclear until the moment the aortic 
root is open inside the operative theatre. No matter how accurate the pre-operative 
diagnostics, intra-operative finding will ultimately guide the ongoing operation.  
The basic principles of operative treatment are: to remove all destroyed tissue, to resolve 
local complications if any, and to anatomically reconstruct the valve if it’s possible or to 
replace it entirely. It is evident that the exclusive involvement of the leaflets makes it easier 
to perform surgical intervention with limited technical difficulty. The problem arises when 
infection spreads beyond the native annulus. 
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Aortic valve replacement (AVR) is the cornerstone operation in setting of aortic valve IE. 
When repair is an option it is preferred over the replacement, although feasibility of aortic 
valve repair is reduced with prevalence of extensive tissue destruction in an aortic IE setting 
(Kwan-Leung & Embli, 2006). Vegetectomy, a novel technique, has also been introduced in 
common practice (Chen et al., 2009). This repair technique may be considered in cases of 
limited vegetation presence and without severe leaflet involvement or extension into 
periannular tissue. Vegetations should not be large in size nor abundantly present because 
the consequent vegetectomy would impair the coaptation process of the valve. Antiobiotic 
therapy before the operation should be aggressive to eliminate the presence of pathogens 
and to reduce the chance of recurrence. 
Several recent studies evaluated outcome after replacement devices were used, that is, 
biological or mechanical valves. The results were generally favourable and have noted no 
significant difference in mortality between the two valve types. The choice of valve type is to 
surgeon’s preference and according to generally accepted indications for AVR. Mechanical 
valves are charcterized as reliable and durable but require lifelong anticoagulation (taken 
orally). Bioprosthesis are limited by their durability of 10-15 years but do not require oral 
anticoagulation therapy. Surgeon needs to be aware of all factors that may influence the 
choice of valve such as patient age, germinative period, risk of haemorrhage or thrombosis 
following oral antiocoagulation therapy compliance and so forth. There is no significant 
difference in either short-term or long-term survival between mechanical and bioprosthetic 
valves. 
In the case of severe aortic root involvement with severe damage of aortic valve and 
surrounding tissue, a composite graft incorporating a prosthetic valve and a vascular tube 
graft can be used. If more than 50% of the aortic annulus has been destroyed, homograft 
(allograft) root replacement may be the treatment of choice. These are the most serious 
conditions that can be seen in aortic root as a consequence of IE. Aortic homograft represent 
the ideal tissue to reconstruct the complicated aortic root as they allow for a radical 
treatment by eliminating abscesses, closing fistulae, the associated treatment of the 
sinotubular junction and ascending aorta, and the implantation of a biological device that 
does not require anticoagulation and is resistant to infection (Mestres et al., 1993). Although 
no conclusive data is available comparing homografts and prosthetic valves with respect to 
durability and risk of recurrent IE, current data from surgical series indicate satisfactory 
results with the use of homografts (Riberi et al., 1997). Another indication for use of 
homograft is PVE which represents a difficult operation with need of extensive removal of 
necrotic tissue and debris (Sabik et al., 2002). A recent study compared 5-year survival rate 
for different valve implant types. It demonstrated that the survival is comparable for 
mechanical valves and homografts, but is significantly lower for bioprosthesis (Nguyen et 
al., 2010). Another research group also investigated relationship between mechanical valves 
and homografts in native valve endocarditis establishing advantage of mechanical 
prosthesis over homografts (Klieverik et al., 2009). 
Stentless aortic valves may also be used for AVR in the case of IE (Perrotta & Lentini, 2010). 
Stentless Aortic Valve Conduit in patients with native or prosthetic aortic valve endocarditis 
appears to demonstrate good results, similar to those of cryopreserved homografts. Study 
comparing two groups of patients treated with stentless valves and homografts, 
demonstrating an equal reinfection rate of 4% and lower mortality for the stentless group 
(12% vs. 16%, respectively). The reinfection rate is found to be lower for the homograft and 
stentless groups than for the patients treated with standard prostheses, respectively, 5.8%, 
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3.7% and 33%. The stentless valve offers a reinfection rate and postoperative 
echocardiographic data comparable to those achieved with homografts (Siniawski et al., 
2003). 
 
Study 
Conduit/ 
prosthesis 
No. 
of pts
Peri-
annular 
aortic 
root 
abscess 
(%) 
Op. 
mortality 
(%) 
Freedom 
from 
recurrent 
infection 
(follow-up 
duration) 
Freedom 
from 
reop. 
(follow-
up) 
Survival 
rate (%) 
(follow-up) 
Yankah  
et al. (2005) 
Homograft in 
NVE 
161 100 9.3 
91%  
(10 years) 
82.9%  
(17 years) 
87  
(11 years) 
Sabik 
et al. (2002) 
Homograft in 
PVE 
103 78 3.9 
95%  
(10 years) 
- 
73 (5 years) 
56  
(10 years) 
Shelhigh 
noreact 
stentless 
prosthesis 
75 100 12 (60 days)
96% (17±10 
months) Siniawski  
et al. (2005) 
Homograft 68 100 16 (60 days)
96% (17±10 
months) 
- 
Kon  
et al. (2002) 
Stentless 
porcine aortic 
root 
bioprosthesis 
104 - 3.9 
96.9%  
(8 years) 
100  
(8 years) 
59.8 
(8 years) 
Schmidtke  
et al. (2007) 
Ross procedure 296 - 0.3 
0  
(47.3 ± 28.6 
months) 
- 
99.7  
(47.3 ± 28.6 
months) 
Homograft 54 63 9 
Avierinos  
et al. (2007) Convent. 
prosthesis 
73 - - 
44 ± 10% (10 years survival-free 
from the combined endpoint, 
including recurrence IE, prosthesis 
dysfunctions and long-term 
cardiovascular mortality) 
 
Table 7. Comparision of multiple conduits for periannular extension of aortic valve 
endocarditis (reproduced with permission from Kang et al., 2009) 
Another suggested procedure that may be used in the setting of IE is the Ross procedure 
(Joyce et al., 1994). The Ross procedure consists of autotransplantation of the pulmonary 
valve. Studies reporting reproducible results following the Ross procedure in the treatment 
of IE have not yet been published in quantity that would allow comparison with other 
available approaches. In the setting of PVE, the Ross procedure should be introduced for 
further improvement of surgical results (Ishikawa et al., 2009). 
Short-term and long-term results following operation due to IE are generally satisfactory. 
There is however a statistical difference in survival among patients with native valve IE and 
PVE. One year survival in native valve endocarditis is reported to be from 91% to 93%, 
while in PVE 79,7%. Five year survival in native valve IE ranges between 54% and 93%, and 
for PVE it is 64,2%. Ten year survival for native valve IE is reported to be from 54% to 67,5%, 
and for PVE from 33.5% to 58% (Kwan-Leung & Embli, 2006). 
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